This phase II trial studies how well daratumumab works in treating transplant-eligible patients with multiple myeloma.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Concurrent therapy considered investigational